ArticleThe Journal of infectious diseases2018
Varicella Zoster Virus Vasculopathy.
Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 3 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2025Pooled it
- Association between herpes zoster and Parkinson's disease and dementia: a systematic review and meta-analysis.Frontiers in neurology · 2024Pooled it
- Stroke risk after varicella-zoster virus infection: a systematic review and meta-analysis.Journal of neurovirology · 2023Pooled it
- Varicella zoster virus infection.Nature reviews. Disease primers · 2026Review
- HSV-1 and VZV co-reactivation: implications for worsening neurological and neurodegenerative diseases.Journal of neurovirology · 2026Review
- Vertebral Artery Stump Syndrome Caused by Varicella-zoster Virus Vasculopathy in the Absence of a Skin Rash.Internal medicine (Tokyo, Japan) · 2026Article
- Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination.Pathogens (Basel, Switzerland) · 2026Review
- Trends and patterns of varicella zoster virus infection in Kilifi: A population-based serosurvey.PLOS global public health · 2026Article
- Article
- Review
- Varicella-zoster virus reactivation and the risk of dementia.Nature medicine · 2025Article
- Herpes Zoster Reactivation in Patients with Coronary Artery Disease.Infection & chemotherapy · 2025Article
- Clinical characteristics and treatment of varicella zoster virus central nervous system infection in an Australian tertiary hospital.Internal medicine journal · 2025Article
- Article
- Periarterial Fat Stranding as a Diagnostic Marker for Visceral Disseminated Varicella-Zoster Virus Infection.Internal medicine (Tokyo, Japan) · 2025Article
- Article
- Post-infectious central nervous system vasculitides in adults: an underdiagnosed and treatable disease part II. Neuroimaging of selected etiologies : Part II. Neuroimaging of selected etiologies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Article
- Expanded spectrum of varicella disease and the need for vaccination in India.Human vaccines & immunotherapeutics · 2024Article
- The effect of herpes zoster vaccination at different stages of the disease course of dementia: Two quasi-randomized studies.medRxiv : the preprint server for health sciences · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Varicella zoster virus (VZV) is a ubiquitous, exclusively human alphaherpesvirus that produces varicella then becomes latent in ganglionic neurons. In elderly and immunocompromised individuals, VZV reactivates and typically produces herpes zoster. Studies of patients with VZV vasculopathy have identified key clinical, imaging, and laboratory features to assist in diagnosis and treatment. Complementary studies have further expanded the spectrum of VZV vasculopathy to include the extracranial circulation and identified mechanisms contributing to its pathogenesis. Given our increasing aging population and recognition that VZV reactivation manifesting as zoster is a risk factor for stroke and myocardial infarction, recognition of VZV as a potential cause of vascular disease with or without associated zoster rash is essential to decrease associated morbidity and mortality because VZV vasculopathy can be treated with antiviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.